Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3438 - Intralesional rose bengal for stage III and IV melanoma


09 Oct 2016


Poster display


Sanjiv Agarwala


Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379


S.S. Agarwala1, R.H.I. Andtbacka2, A. Hauschild3, K.N. Rice4, M. Ross5, C.R. Scoggins6, M. Smithers7, E. Whitman8, E.A. Wachter9

Author affiliations

  • 1 Cancer Center, St. Luke's Hospital & Health Network, 18015 - Bethlehem/US
  • 2 Surgical Oncology, Huntsman Cancer Institute, Salt Lake City/US
  • 3 Department Of Dermatology, University of Kiel (UKSH), 24105 - Kiel/DE
  • 4 Hematology/oncology, Sharp Memorial Hospital, San Diego/US
  • 5 Surgical Oncology, MD Anderson Cancer Center, Houston/US
  • 6 Surgical Oncology, University of Louisville, Louisville/US
  • 7 The University Of Queensland, Princess Alexandra Hospital, Brisbane/AU
  • 8 Oncology, Atlantic Melanoma Center, Morristown/US
  • 9 Clinical Development, Provectus Biopharmaceuticals, Knoxville/US


Abstract 3438


Intralesional rose bengal (PV-10) is an investigational small molecule ablative immunotherapy that can elicit primary ablation of injected tumors and anti-tumor immune response via secondary T-cell activation. Phase 2 testing in Stage III-IV melanoma yielded a 51% objective response rate (ORR) with 50% complete response (CR) when all disease was injected. PV-10 is currently undergoing phase 3 testing as a single agent in patients with locally advanced cutaneous melanoma and phase 1b testing in combination with immune checkpoint inhibition for more advanced disease.

Trial design

Study PV-10-MM-31 (NCT02288897) is an international multicenter, open-label, randomized controlled trial of PV-10 versus investigator's choice of chemotherapy (dacarbazine or temozolomide) or oncolytic viral therapy (talimogene laherparepvec). A total of 225 subjects with locally advanced cutaneous melanoma (Stage IIIB, IIIC or IV-M1a melanoma) randomized 2:1 will be assessed for progression free survival (PFS) by RECIST 1.1 (using blinded Independent Review Committee assessment of study photography and radiology data). Comprehensive disease assessments, including review of photography and radiology data, are performed at 12 week intervals; clinical assessments of progression status are performed at 28-day intervals. Study PV-10-MM-1201 (NCT02557321) is an international multicenter, open-label, sequential phase study of PV-10 in combination with pembrolizumab. Stage IV metastatic melanoma patients with at least one injectable cutaneous or subcutaneous lesion who are candidates for pembrolizumab are eligible. In the current phase 1b portion of the study, up to 24 subjects will receive the combination of PV-10 and pembrolizumab (PV-10 + standard of care). In phase 2 an estimated 120 participants will be randomized 1:1 to receive either PV-10 and pembrolizumab or pembrolizumab alone. The primary endpoint for phase 1b is safety and tolerability with PFS a key secondary endpoint; PFS is the primary endpoint for phase 2.

Clinical trial identification

NCT02288897; NCT02557321

Legal entity responsible for the study

Provectus Biopharmaceuticals, Inc.


Provectus Biopharmaceuticals, Inc.


E.A. Wachter: Employee and shareholder of Provectus, sponsor of the subject clinical trials. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings